Open AccessFluvoxamine Treatment of Patients with Symptomatic COVID-19 in a Community Treatment Center: A Preliminary Result of Randomized Controlled Trial
Author(s) -
Hyeonji Seo,
Haein Kim,
Seongman Bae,
Seonghee Park,
Hyemin Chung,
Heungsup Sung,
Min Jae Kim,
SangOh Lee,
SangHo Choi,
Yang-Soo Kim,
Kiyoung Son,
Yong Pil Chong
Publication year - 2022
Publication title -
infection and chemotherapy/gam'yeom gwa hwahag yo'beob/infection and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.724
H-Index - 26
eISSN - 2092-6448
pISSN - 1598-8112
DOI - 10.3947/ic.2021.0142
Subject(s) - medicine , interquartile range , randomized controlled trial , pneumonia , clinical trial , placebo , randomization , adverse effect , community acquired pneumonia , alternative medicine , pathology
This study aimed to evaluate whether fluvoxamine reduces clinical deterioration in adult patients with mild to moderate coronavirus disease 2019 (COVID-19), and to identify risk factors for clinical deterioration in patients admitted to a community treatment center (CTC).